Secondary malignant neoplasm of skin
ICD-10 C79.2 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of skin.
C79.2 refers to secondary malignant neoplasms of the skin, which are metastatic skin lesions originating from primary cancers located elsewhere in the body. These lesions can arise from various malignancies, including but not limited to breast, lung, and melanoma. The skin serves as a common site for metastasis due to its extensive vascular supply and lymphatic drainage. Clinically, these lesions may present as nodules, plaques, or ulcerated areas, and they can vary in appearance based on the primary tumor type. Diagnosis typically involves a combination of imaging studies, such as CT or MRI, and biopsy to confirm malignancy. Staging of secondary skin neoplasms is crucial for determining prognosis and treatment options, often utilizing the TNM (Tumor, Node, Metastasis) system. Palliative care considerations are essential, as many patients with secondary skin malignancies may have advanced disease, necessitating symptom management and quality of life improvements. Treatment may include local therapies, systemic chemotherapy, or immunotherapy, depending on the primary cancer type and extent of disease.
Comprehensive documentation of the primary cancer diagnosis, staging, and treatment history.
Patients with known malignancies presenting with new skin lesions.
Ensure clear documentation of the metastatic nature and any treatments provided.
Detailed descriptions of skin lesions, including size, location, and appearance.
Evaluation of skin lesions in patients with a history of cancer.
Differentiation between primary skin cancers and metastatic lesions is crucial.
Used when a skin lesion is biopsied to confirm metastatic disease.
Document the location, size, and appearance of the lesion.
Oncology specialists should ensure the primary cancer history is noted.
Primary malignant neoplasms originate in the skin itself, while secondary malignant neoplasms are metastatic lesions that have spread to the skin from another primary cancer site.
